目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 19)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 GEOGRAPHICAL SCOPE
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 23)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 1 GLYCATED ALBUMIN ASSAY MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY DATA
2.2.2.1 Primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Approach 1: Company revenue estimation approach
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 Approach 2: Primary interviews
2.3.1.3 Growth forecast
2.3.1.4 Glycated Albumin Assay Industry: CAGR Projections
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 6 MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION METHODOLOGY
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 STUDY ASSUMPTIONS
2.7 STUDY LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
2.9 RISK ASSESSMENT
2.9.1 MARKET: RISK ASSESSMENT ANALYSIS
2.10 RECESSION IMPACT ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 37)
FIGURE 8 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 9 GLYCATED ALBUMIN ASSAY INDUSTRY, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 10 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 40)
4.1 GLYCATED ALBUMIN ASSAY MARKET OVERVIEW
FIGURE 11 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET
4.2 GLYCATED ALBUMIN ASSAY INDUSTRY, BY APPLICATION, 2023 VS. 2028
FIGURE 12 TYPE 2 DIABETES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.3 MARKET, BY END USER, 2023 VS. 2028
FIGURE 13 HOSPITALS AND DIABETIC CARE CENTERS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 43)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 GLYCATED ALBUMIN ASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of diabetes
FIGURE 16 PREVALENCE OF DIABETES IN ADULTS (20-79 YEARS), BY REGION, 2021 VS. 2045 (USD MILLION)
TABLE 1 TOTAL HEALTH EXPENDITURE (USD) FOR DIABETES (20-79 YEARS), BY COUNTRY (2021)
5.2.1.2 Growing focus on early detection of diabetes
5.2.1.3 Increase in age-associated diabetic ailments
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.3 OPPORTUNITIES
5.2.3.1 Rising investments in life sciences research
5.2.4 CHALLENGES
5.2.4.1 Stringent regulatory requirements for diagnostic products
5.2.4.2 Presence of alternative tests
5.3 PRICING ANALYSIS
TABLE 2 AVERAGE SELLING PRICE OF GLYCATED ALBUMIN ASSAY PRODUCTS
5.4 PATENT ANALYSIS
FIGURE 17 PATENT ANALYSIS FOR GLYCATED ALBUMIN ASSAYS (JANUARY 2013-DECEMBER 2022)
5.4.1 GLYCATED ALBUMIN ASSAY INDUSTRY: LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 18 MARKET: MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 19 MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
FIGURE 20 MARKET: ECOSYSTEM MAP
5.7.1 MARKET: ECOSYSTEM ROLE
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 INTENSITY OF COMPETITIVE RIVALRY
5.9 REGULATORY LANDSCAPE
TABLE 4 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 MIDDLE EAST: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.9.1 NORTH AMERICA
5.9.1.1 US
5.9.1.2 Canada
5.9.2 EUROPE
TABLE 8 EUROPE: CLASSIFICATION OF DEVICES
5.9.3 ASIA PACIFIC
5.9.3.1 China
5.9.3.2 Japan
5.9.3.3 India
5.9.4 LATIN AMERICA
5.9.4.1 Brazil
5.9.4.2 Mexico
5.9.5 MIDDLE EAST
5.9.6 AFRICA
5.10 TRADE ANALYSIS
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.10.1.1 Import data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
5.10.1.2 Export data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
5.11 TECHNOLOGY ANALYSIS
5.12 KEY CONFERENCES AND EVENTS
TABLE 9 DETAILED LIST OF CONFERENCES AND EVENTS (2022−2023)
5.13 PESTLE ANALYSIS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 21 MARKET: REVENUE SHIFT MAPPING
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR GLYCATED ALBUMIN ASSAYS
TABLE 10 MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
5.15.2 BUYING CRITERIA
FIGURE 23 MARKET: KEY BUYING CRITERIA
TABLE 11 KEY BUYING CRITERIA FOR GLYCATED ALBUMIN ASSAYS, BY END USER
5.16 CASE STUDY ANALYSIS
FIGURE 24 CASE STUDY ANALYSIS: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOR IN INDIA

6 GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION (Page No. - 68)
6.1 INTRODUCTION
TABLE 12 GLYCATED ALBUMIN ASSAY INDUSTRY, BY APPLICATION, 2021-2028 (USD MILLION)
6.2 TYPE 2 DIABETES
6.2.1 DIETARY AND LIFESTYLE CHANGES TO CONTRIBUTE TO MARKET GROWTH
TABLE 13 MARKET FOR TYPE 2 DIABETES, BY REGION, 2021-2028 (USD MILLION)
6.3 PREDIABETES
6.3.1 INSULIN RESISTANCE AND RISING CASES OF PREDIABETES TO DRIVE MARKET
TABLE 14 MARKET FOR PREDIABETES, BY REGION, 2021-2028 (USD MILLION)
6.4 TYPE 1 DIABETES
6.4.1 INCREASING INCIDENCE AMONG CHILDREN AND ADOLESCENTS TO SUPPORT MARKET GROWTH
TABLE 15 INCIDENCE OF TYPE 1 DIABETES IN CHILDREN AND ADOLESCENTS AGED 0 TO 19, BY REGION, 2021 (THOUSANDS)
TABLE 16 MARKET FOR TYPE 1 DIABETES, BY REGION, 2021-2028 (USD MILLION)

7 GLYCATED ALBUMIN ASSAY MARKET, BY END USER (Page No. - 74)
7.1 INTRODUCTION
TABLE 17 GLYCATED ALBUMIN ASSAY INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
7.2 HOSPITALS AND DIABETES CARE CENTERS
7.2.1 ABILITY TO OFFER RAPID RESULTS IN ACCESSIBLE SETTING TO DRIVE MARKET
TABLE 18 MARKET FOR HOSPITALS AND DIABETES CARE CENTERS, BY REGION, 2021-2028 (USD MILLION)
7.3 DIAGNOSTIC LABORATORIES
7.3.1 RISING OUTSOURCING OF RESEARCH ACTIVITIES FOR COST REDUCTION TO DRIVE MARKET
TABLE 19 MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
7.4 OTHER END USERS
TABLE 20 MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

8 GLYCATED ALBUMIN ASSAY MARKET, BY REGION (Page No. - 79)
8.1 INTRODUCTION
TABLE 21 GLYCATED ALBUMIN ASSAY INDUSTRY, BY REGION, 2021-2028 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 25 NORTH AMERICA: MARKET SNAPSHOT
TABLE 22 NORTH AMERICA: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 23 NORTH AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 24 NORTH AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.2.1 US
8.2.1.1 High healthcare expenditure for diabetes treatment & diagnosis to drive market
TABLE 25 US: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 26 US: GLYCATED ALBUMIN ASSAY INDUSTRY, BY END USER, 2021-2028 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Rising awareness of early diabetes detection to support market growth
TABLE 27 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029
TABLE 28 CANADA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 29 CANADA: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.2.3 NORTH AMERICA: RECESSION IMPACT
8.3 EUROPE
TABLE 30 PREVALENCE OF DIABETES IN EUROPE, 2021 VS. 2045
TABLE 31 EUROPE: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 32 EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 33 EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Provision of healthcare coverage for technologically advanced assays to drive market
TABLE 34 GERMANY: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 35 GERMANY: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.3.2 UK
8.3.2.1 Rising geriatric population and diabetes-associated ailments to drive market
TABLE 36 UK: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 37 UK: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Increasing R&D expenditure for product commercialization to drive market
TABLE 38 FRANCE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 39 FRANCE: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.3.4 ITALY
8.3.4.1 Improvements in healthcare infrastructure to support market growth
TABLE 40 ITALY: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 41 ITALY: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.3.5 SPAIN
8.3.5.1 Rising incidence of diabetes among senior women to support market growth
TABLE 42 SPAIN: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 43 SPAIN: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.3.6 REST OF EUROPE
TABLE 44 REST OF EUROPE: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 45 REST OF EUROPE: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.3.7 EUROPE: RECESSION IMPACT
8.4 ASIA PACIFIC
FIGURE 26 ASIA PACIFIC: MARKET SNAPSHOT
TABLE 46 ASIA PACIFIC: MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
TABLE 47 ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 48 ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.4.1 CHINA
8.4.1.1 Improving healthcare infrastructure to propel market
TABLE 49 CHINA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 50 CHINA: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.4.2 JAPAN
8.4.2.1 Universal healthcare reimbursement policy to support market growth
TABLE 51 JAPAN: GLYCATED ALBUMIN ASSAY MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 52 JAPAN: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.4.3 INDIA
8.4.3.1 implementation of favorable government initiatives to drive market
TABLE 53 INDIA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 54 INDIA: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.4.4 REST OF ASIA PACIFIC
TABLE 55 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 56 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.4.5 ASIA PACIFIC: RECESSION IMPACT
8.5 LATIN AMERICA
8.5.1 RISING GOVERNMENT-FUNDED PROGRAMS FOR ACCURATE AND EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
TABLE 57 LATIN AMERICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 58 LATIN AMERICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.5.2 LATIN AMERICA: RECESSION IMPACT
8.6 MIDDLE EAST & AFRICA
8.6.1 EXPANSION OF KEY MARKET PLAYERS TO SUPPORT MARKET GROWTH
TABLE 59 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021-2028 (USD MILLION)
8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

9 COMPETITIVE LANDSCAPE (Page No. - 106)
9.1 OVERVIEW
9.2 REVENUE SHARE ANALYSIS OF LEADING MARKET PLAYERS
FIGURE 27 GLYCATED ALBUMIN ASSAY MARKET: REVENUE SHARE ANALYSIS
9.3 MARKET SHARE ANALYSIS
9.3.1 MARKET
FIGURE 28 MARKET SHARE, BY KEY PLAYER (2022)
TABLE 61 MARKET: INTENSITY OF COMPETITIVE RIVALRY
9.4 MARKET: COMPANY EVALUATION MATRIX
9.4.1 STARS
9.4.2 EMERGING LEADERS
9.4.3 PERVASIVE PLAYERS
9.4.4 PARTICIPANTS
FIGURE 29 MARKET: COMPANY EVALUATION MATRIX (2022)
9.5 MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
9.5.1 PROGRESSIVE COMPANIES
9.5.2 STARTING BLOCKS
9.5.3 RESPONSIVE COMPANIES
9.5.4 DYNAMIC COMPANIES
FIGURE 30 MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
9.6 COMPETITIVE BENCHMARKING
9.6.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
FIGURE 31 MARKET: PRODUCT AND REGIONAL FOOTPRINT ANALYSIS
TABLE 62 MARKET: COMPETITIVE EVALUATION OF KEY PLAYERS
TABLE 63 MARKET: COMPANY PRODUCT FOOTPRINT
TABLE 64 MARKET: COMPANY REGIONAL FOOTPRINT

10 COMPANY PROFILES (Page No. - 113)
(Business overview, Products offered, Recent Developments, MNM view)*
10.1 KEY PLAYERS
10.1.1 ASAHI KASEI CORPORATION
TABLE 65 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
FIGURE 32 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022)
10.1.2 BEIJING STRONG BIOTECHNOLOGIES, INC.
TABLE 66 BEIJING STRONG BIOTECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 33 BEIJING STRONG BIOTECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
10.1.3 DIAZYME LABORATORIES, INC.
TABLE 67 DIAZYME LABORATORIES, INC.: COMPANY OVERVIEW
10.1.4 DXGEN CORP.
TABLE 68 DXGEN CORP: COMPANY OVERVIEW
10.1.5 WELDON BIOTECH, INC.
TABLE 69 WELDON BIOTECH, INC.: COMPANY OVERVIEW
10.1.6 HZYMES BIOTECH
TABLE 70 HZYMES BIOTECH: COMPANY OVERVIEW
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

11 APPENDIX (Page No. - 120)
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS